Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.

MLA

Breccia, Massimo, et al. “Tyrosine Kinase Inhibitor Discontinuation in the Management of Chronic Myeloid Leukemia: A Critical Review of the Current Practice.” Expert Review of Hematology, vol. 13, no. 12, Dec. 2020, pp. 1311–18. EBSCOhost, https://doi.org/10.1080/17474086.2021.1852924.

APA

Breccia, M., Efficace, F., Colafigli, G., Scalzulli, E., Di Prima, A., Martelli, M., & Foà, R. (2020). Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. Expert Review of Hematology, 13(12), 1311–1318. https://doi.org/10.1080/17474086.2021.1852924

Chicago

Breccia, Massimo, Fabio Efficace, Gioia Colafigli, Emilia Scalzulli, Alessio Di Prima, Maurizio Martelli, and Robin Foà. 2020. “Tyrosine Kinase Inhibitor Discontinuation in the Management of Chronic Myeloid Leukemia: A Critical Review of the Current Practice.” Expert Review of Hematology 13 (12): 1311–18. doi:10.1080/17474086.2021.1852924.